Pertussis Treatment Market

Pertussis Treatment Market Outlook (2024 to 2034)

The global pertussis treatment market size has been projected at a value of US$ 3.8 billion in 2024. The market is forecasted to advance at a CAGR of 3.4% and reach a size of US$ 5.3 billion by the end of 2034.

Pertussis is a respiratory disease, also referred to as whooping cough, which affects the nose and throat. Whooping cough can be treated through medication, vaccination, and/or supportive treatment. Pertussis vaccination administered intravenously is believed to effectively treat whooping cough-causing Borrelia bacteria.

• Worldwide sales of pertussis vaccinations are forecasted to reach US$ 1.37 billion by 2034-end.
• The North American pertussis treatment market size is estimated at US$ 1.48 billion in 2024.
• Western Europe is projected to capture 19.5% of the global pertussis treatment market share by 2034.

Children and infants are most vulnerable to whooping cough, and it can spread quickly from one person to another. This contagious pertussis disease shows symptoms such as low temperature, runny nose, and cough. Immunization or vaccination is one of the best pertussis treatment remedies out there.

• According to the Centers for Disease Control and Prevention (CDC), an estimated 24.1 million cases of pertussis and 160,700 deaths in children younger than age 5 years are recorded annually, worldwide.
• As per the article 'Highly contagious Whooping Cough spreads globally; Know all about its causes, symptoms and treatment', published by Financial Express on 12th April 2024, cases of whooping cough are increasing rapidly across the world, especially in the United Kingdom, China, the Philippines, Czech Republic, the Netherlands, and the United States.

Report Attribute	Detail
Pertussis Treatment Market Size (2024E)	US$ 3.8 Billion
Forecasted Market Value (2034F)	US$ 5.3 Billion
Global Market Growth Rate (2024 to 2034)	3.4% CAGR
South Korea Market Size (2024E)	US$ 131 Million
Canada Market Growth Rate (2024 to 2034)	5.1% CAGR
Market Share of Parenteral Pertussis Drugs (2034)	30.3%
Key Companies Profiled	Johnson & Johnson Services Inc.; GlaxoSmithKline, Plc.; Merck & Co. Inc.; Sanofi; Pfizer Inc.; Novartis AG; Panacea Biotech; China National Biotec Group; Changchun Changsheng Life Sciences; Daiichi Sankyo Company Ltd.; Mylan NV; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Mitsubishi Tanabe Pharma; Astellas Pharma; Shenzhen KangTai Biological Products.

What’s Positively Influencing Sales of Pertussis Drugs Across the World?

“Rising Prevalence of New and Old Contagious Diseases Driving Investments in Innovative Drug Production”

The prevalence of contagious diseases has been increasing across the globe. Urbanization, living in more densely populated areas, surge in traveling activities, and increasing pet ownership are some of the key factors giving rise to concerns about new infectious diseases. There is also a high chance that infectious diseases can get transferred from animals to humans.

The recent COVID pandemic is the best example of the risks of contagious disease. Governments in several countries are investing in R&D activities to introduce effective vaccinations and medications. The rising prevalence of infectious diseases, including whooping cough, is set to drive demand for target treatments.

“Advancements in Polymerase Chain Reaction (PCR) and Serological Assays”

A notable pertussis treatment market trend is rapid advancements in diagnostic technologies, including polymerase chain reaction (PCR) and serological assays.

• According to the European Centre for Disease Prevention and Control, for patients coughing for 2 to 3 weeks or longer, serologic diagnosis is an effective method for pertussis detection.
• The Centers for Disease Control and Prevention (CDC) estimates that the polymerase chain reaction (PCR) is a vital and effective molecular technique to detect Bordetella pertussis bacterium.

Polymerase chain reaction can effectively detect small amounts of bacterial DNA from Bordetella pertussis bacterium. High sensitivity aids in accurate and earlier diagnosis compared to traditional methods. Serological assays offer vital information on past exposure or immunity status, helping in epidemiological studies and vaccine efficacy assessments.

What’s Denting the Profits of Pertussis Treatment Solution Providers?

“High Cost of Pertussis Medicine Production and Storage”

Developing vaccines needs extremely high capital investments. Substantial investments in research and development activities have led to the production of effective and reliable pertussis vaccinations, drugs, medications, and other therapeutic solutions. Also, the storage and shipping costs of vaccines are higher than other pharma medications since they need special monitoring and transportation solutions.

Lack of appropriate storage and transport facilities is a key factor hampering whooping cough vaccine quality and shelf life. Thus, from in vitro research to marketing, pertussis medicine requires significant investments. Therefore, this high cost of vaccine production is limiting global pertussis treatment market growth to some extent.

How Can New Companies Bolster Their Market Presence?

“Focus on Development of Innovative Treatment Approaches”

New companies should focus on investing in R&D for the development of novel therapies or innovative drug production. Advancements in pertussis therapeutics will help them stand apart from the crowd. New drug or vaccine formulations, delivery methods, and combination therapies aimed at enhancing efficacy and patient compliance will be key in this business space.

Country-wise Analysis

Why is Demand for Pertussis Therapeutics Rising in the United States?

“Increasing Prevalence of Pertussis and Presence of Advanced Healthcare Facilities”

Attribute	United States
Market Value (2024E)	US$ 1.29 Billion
Growth Rate (2024 to 2034)	3.9% CAGR
Projected Value (2034F)	US$ 1.89 Billion

• According to a Centers for Disease Control and Prevention (CDC) report, around 5,611 people in the United States were detected with pertussis in 2023.

This rising prevalence of pertussis in the country is driving high demand for effective therapeutic solutions. Presence of cutting-edge healthcare facilities and continuous advancements in diagnostic technologies are set to drive pertussis treatment demand growth in the country over the coming years.

What is the Demand Outlook for Pertussis Medications in Japan?

“Large Older Demographic More Susceptible to Pertussis Disease”

Attribute	Japan
Market Value (2024E)	US$ 163.3 Million
Growth Rate (2024 to 2034)	1.1% CAGR
Projected Value (2034F)	US$ 181.9 Million

Large aging population in Japan has led to increased susceptibility to infectious diseases, including pertussis. This risk of pertussis among older people will drive the need for effective treatment solutions in the country. Health campaigns and education initiatives conducted by the government are also contributing to market growth in Japan. Availability of advanced diagnostic techniques and medications will benefit pertussis therapeutic providers in the country.

Category-wise Analysis

Which Mode of Purchase is Most Relied on for Pertussis Medications?

“Rx Mode of Purchase Most Prevalent Worldwide”

Attribute	Rx Mode of Purchase
Segment Value (2024E)	US$ 2.9 Billion
Growth Rate (2024 to 2034)	3.4% CAGR
Projected Value (2034F)	US$ 4.04 Billion

Pertussis severity and complications can vary based on when and how it is detected. A majority of patients prefer treatment from hospitals or specialized clinics. Accordingly, doctors need to prescribe effective and safe medications to patients. This factor makes Rx or prescribed pertussis medications the most prevalent in the market, with the segment accounting for over three-fourths of sales.

Which is the Prime Distribution Channel for Pertussis Drugs and Medications?

“Hospital Pharmacies Lead Sales of Pertussis Medications”

Attribute	Hospital Pharmacies
Segment Value (2024E)	US$ 1.52 Billion
Growth Rate (2024 to 2034)	3.1% CAGR
Projected Value (2034F)	US$ 2.07 Billion

As already mentioned, most patients primarily prefer hospitals for pertussis treatment and other infectious diseases. Direct patient access allows hospital pharmacies to ensure timely and appropriate dispensation of medications to target patients. Hospital pharmacies are equipped with skilled pharmacists and stocked with advanced medications. This leads to the high sales of pertussis medications through hospital pharmacies.

Competitive Landscape

Key players in the pertussis treatment market are adopting several organic and inorganic strategies such as mergers & acquisitions, collaborations, partnerships, new product offerings, and regional expansion to stay ahead of the competition. They are partnering with other companies to increase their market reach. Collaborating with research institutions is also aiding in increasing their product offerings.

• 25 March 2024: As per a press release by EurekAlert, researchers from the American Society for Biochemistry and Molecular Biology uncovered a key biomolecule involved in pertussis infection. The discovery is expected to aid in creating a new drug or vaccine for whooping cough.

Fact.MR provides detailed information about the price points of key providers of pertussis treatment solutions positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Key Segments of Pertussis Treatment Market Research

• By Type :

  • Medications
  • Vaccinations
  • Supportive Treatments
  • Others

• By Diagnosis :

  • Blood Tests
  • Chest X-Rays
  • Nose or Throat Culture & Tests

• By Mode of Purchase :

  • Rx
  • OTC

• By Route of Administration :

  • Oral
  • Parenteral
  • Others

• By Disease Stage :

  • Incubation Stage
  • Catarrhal Stage
  • Paroxysmal Stage
  • Convalescent Stage

• By Distribution Channel :

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa